Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 32Unknown 5Terminated 4Recruiting 3Active not recruiting 3Suspended 2

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Locally Recurrent Skin Squamous Cell Carcinoma 1Colorectal Neoplasms 1

Interventions

Specimen Handling 19Biopsy 13Magnetic Resonance Spectroscopy 11Cyclophosphamide 4X-Rays 3Vincristine 3Nivolumab 3Doxorubicin 3venetoclax 2trastuzumab deruxtecan 2decitabine and cedazuridine drug combination 2Taxes 2Surgical Procedures, Operative 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Prednisone 2Ipilimumab 2Cetuximab 2CTLA-4 Antigen 2Azacitidine 2Actinium 2(225)Ac-DOTA-c(RGDyK) 2sargramostim 1relatlimab 1prednylidene 1olaparib 1neratinib 1mirdametinib 1ipatasertib 1iadademstat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × NIH × Cetuximab × Clear all
NCT07042295 2026-05-27

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

National Cancer Institute (NCI)

Phase 2 Suspended
86 enrolled

Locally Recurrent Skin Squamous Cell Carcinoma

NCT06102902 2026-05-13

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡